- severe covid-19 is defined by one or more of the following: - blood oxygen saturation ≤ 90% - partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 - lung infiltrates ≥ 50% within 24 to 48 hours - life-threatening covid-19 is defined as one or more of the following: - respiratory failure - septic shock - multiple organ dysfunction or failure - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c - existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. - uncontrolled seizure disorder - subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. - patients with reflux esophagitis after surgery. - known allergy to artemisia annua or camostat mesilate. - currently receiving any study medications for other indications. - concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: - patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. - receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. - cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. - patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - enrollment on other experimental therapies for covid-19. - inability to receive enteral medications - patients with psychiatric illness/social situations that would limit compliance with study requirements. - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - any other condition that in the opinion of the treating physician justifies exclusion from the study.

- severe covid-19 is defined by one or more of the following: - blood oxygen saturation ≤ 90% - partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300 - lung infiltrates ≥ 50% within 24 to 48 hours - life-threatening covid-19 is defined as one or more of the following: - respiratory failure - septic shock - multiple organ dysfunction or failure - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - subjects who need antiviral administration due to severe viral diseases other than covid-19, such as hiv, hepatitis b, and hepatitis c - existing division of microbiology and infectious disease toxicity scale for determining the severity of adverse events grade 3 or greater. - uncontrolled seizure disorder - subjects with reflux esophagitis after chronic pancreatitis and gastrectomy surgery. - patients with reflux esophagitis after surgery. - known allergy to artemisia annua or camostat mesilate. - currently receiving any study medications for other indications. - concurrent use of medication that would cause moderate or severe due to drug-drug interactions with study medication. specifically: - patients receiving artemisia annua tea may not be currently taking strong inducers of cyp2a6, including phenobarbital and rifampin. - receipt in the 12 hours prior to enrollment, or planned administration during the 14-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; or sotalol. - cancer patients receiving active immunosuppressive treatment cannot be enrolled unless they are on a treatment holiday with no antineoplastic treatment with 3 weeks of enrollment. - patients with genetic problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - enrollment on other experimental therapies for covid-19. - inability to receive enteral medications - patients with psychiatric illness/social situations that would limit compliance with study requirements. - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - any other condition that in the opinion of the treating physician justifies exclusion from the study.